Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
BOTHELL, Wash., May 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2024, and provided recent pipeline and business updates.
- Athira expects to report topline data from LIFT-AD in the second half of 2024.
- Athira expects to initiate a first-in-human study of ATH-1105 in the second quarter of 2024.
- R&D expenses were $21.2 million for the quarter ended March 31, 2024, compared to $21.3 million for the quarter ended March 31, 2023.
- G&A expenses were $6.5 million for the quarter ended March 31, 2024, compared to $8.5 million for the quarter ended March 31, 2023.